Can treatment response to SGLT2-inhibitors in syndrome of inappropriate antidiuresis be predicted by copeptin, natriuretic peptides and inflammatory markers?

Rianne Nobbenhuis Julie C Refardt Deborah R Vogt Clara Odilia Sailer Bettina Winzeler Mirjam Christ-Crain

Published in: Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals (2021)

Based on our data, no biomarker could be identified as predictor for treatment response to empagliflozin. Urinary sodium was confirmed as a good marker for non-response to fluid restriction in SIAD patients. Clinical trial registration: ClinicalTrials.gov (Number: NCT02874807).

Keyphrases

clinical trial
ejection fraction
end stage renal disease
newly diagnosed
chronic kidney disease
prognostic factors
randomized controlled trial
open label
study protocol
machine learning
case report
big data
double blind